Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals began enrolling patients in the STORM (Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma) trial. The randomized, double-blind, placebo-controlled Phase III study is evaluating Nexavar (sorafenib) tablets as adjuvant treatment for patients with hepatocellular carcinoma (HCC), or primary liver cancer.     “Nexavar is the only systemic therapy with proven efficacy and tolerability in HCC acr...